Abstract: With the development of various targeted drugs, the treatments of myeloid neoplasms have made a breakthrough. As a selective B-cell lymphoma-2 (Bcl-2) inhibitor, venetoclax can inhibit the expression of anti-apoptotic Bcl-2 proteins, regulate the mitochondrial pathway of apoptosis, and induce tumor cell death. Venetoclax monotherapy and combination therapy have shown positive clinical efficacy for myeloid neoplasms. At present the common treatment is venetoclax in combination with hypomethylating agents (HMAs) or low dose cytarabine (LDAC). Currently, the research focus is mainly on the combination of venetoclax with other small molecule inhibitors targeting gene mutations or apoptotic pathways. This review summarizes the progress on venetoclax for the treatment of myeloid neoplasms.